Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotech company focused on kidney disease therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's CEO, Dr. Shalabh Gupta, is scheduled to present a corporate update on September 10, 2024, at 10:30 a.m. ET in New York.
Investors and interested parties can access the live and archived webcast of the presentation through the Unicycive website's Investors section under Events and Presentations. The archived webcast will remain available for three months following the event, providing an extended opportunity for stakeholders to gain insights into the company's latest developments and strategic direction.
Unicycive Therapeutics (Nasdaq: UNCY), una compagnia biotech in fase clinica focalizzata sulle terapie per le malattie renali, ha annunciato la sua partecipazione al 26° Annual Global Investment Conference di H.C. Wainwright. Il CEO dell'azienda, Dr. Shalabh Gupta, presenterà un aggiornamento aziendale il 10 settembre 2024, alle 10:30 a.m. ET a New York.
Investitori e parti interessate possono accedere alla webcast dal vivo e registrata della presentazione tramite la sezione Investitori del sito web di Unicycive, sotto Eventi e Presentazioni. La webcast registrata rimarrà disponibile per tre mesi dopo l'evento, offrendo un’opportunità estesa per gli stakeholder di ottenere informazioni sugli ultimi sviluppi e sulla direzione strategica dell'azienda.
Unicycive Therapeutics (Nasdaq: UNCY), una empresa biotech en fase clínica centrada en terapias para enfermedades renales, ha anunciado su participación en la 26ª Conferencia Anual de Inversiones Globales de H.C. Wainwright. El CEO de la compañía, Dr. Shalabh Gupta, tiene programada una actualización corporativa el 10 de septiembre de 2024, a las 10:30 a.m. ET en Nueva York.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo y grabada de la presentación a través de la sección de Inversores en el sitio web de Unicycive, bajo Eventos y Presentaciones. La transmisión grabada permanecerá disponible durante tres meses después del evento, brindando una oportunidad extendida para que los interesados obtengan información sobre los últimos desarrollos y la dirección estratégica de la empresa.
유니사이브 테라퓨틱스 (Nasdaq: UNCY), 신장 질환 치료를 중심으로 하는 임상 단계 생명공학 회사는 H.C. 웨인라이트 제26회 글로벌 투자 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 CEO인 Dr. Shalabh Gupta는 2024년 9월 10일 오전 10:30 (ET) 에 뉴욕에서 기업 업데이트를 발표할 예정입니다.
투자자와 이해관계자는 유니사이브 웹사이트의 투자자 섹션에서 행사 및 발표 아래에 있는 실시간 및 기록된 웹캐스트에 액세스할 수 있습니다. 기록된 웹캐스트는 3개월 동안 행사 후에 이용 가능하여 이해관계자들이 회사의 최신 개발 및 전략적 방향에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Unicycive Therapeutics (Nasdaq: UNCY), une entreprise de biotechnologie en phase clinique axée sur les thérapies pour les maladies rénales, a annoncé sa participation à la 26ème Conférence Annuelle d'Investissement Mondial H.C. Wainwright. Le CEO de la société, Dr. Shalabh Gupta, est prévu pour présenter une mise à jour de l'entreprise le 10 septembre 2024, à 10h30 ET à New York.
Les investisseurs et les parties intéressées peuvent accéder à la webdiffusion en direct et enregistrée de la présentation via la section Investisseurs du site Web d'Unicycive sous Événements et Présentations. La webdiffusion enregistrée restera disponible pendant trois mois après l'événement, offrant ainsi une occasion prolongée aux parties prenantes d'obtenir des informations sur les derniers développements et la direction stratégique de l'entreprise.
Unicycive Therapeutics (Nasdaq: UNCY), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Therapien für Nierenerkrankungen konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Der CEO des Unternehmens, Dr. Shalabh Gupta, wird am 10. September 2024 um 10:30 Uhr ET in New York eine Unternehmensaktualisierung präsentieren.
Investoren und Interessierte können die Live- und aufgezeichnete Webcast der Präsentation über den Bereich Investoren auf der Website von Unicycive unter Veranstaltungen und Präsentationen abrufen. Der aufgezeichnete Webcast bleibt drei Monate nach der Veranstaltung verfügbar, sodass die Beteiligten eine erweiterte Gelegenheit haben, Einblicke in die neuesten Entwicklungen und die strategische Ausrichtung des Unternehmens zu erhalten.
- None.
- None.
LOS ALTOS, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024 at 10:30 a.m. ET in New York, NY.
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn, X, and YouTube.
Investor Contact:
ir@unicycive.com
(650) 543-5470
SOURCE: Unicycive Therapeutics, Inc.
FAQ
When is Unicycive Therapeutics (UNCY) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting the corporate update for Unicycive Therapeutics (UNCY)?
How can investors access the webcast of Unicycive Therapeutics' (UNCY) presentation?
How long will the archived webcast of Unicycive Therapeutics' (UNCY) presentation be available?
What is the main focus of Unicycive Therapeutics (UNCY) as a company?
